A Phase 1 interventional study of ALK Grass tablet in Allergy, sponsored by ALK-Abelló A/S. Completed at 1 site in Germany. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2006-05-04.
Sponsored by ALK-Abelló A/S · Phase 1 and Interventional
This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.
1,916 studies on the registry are indexed under Hypersensitivity; 265 are open to participants now.
This study's enrollment of 50 is below the median of 57 across 1,384 interventional studies indexed under Hypersensitivity.
Browse Hypersensitivity studies →ALK-Abelló A/S is the lead sponsor of 66 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Assessment of safety by recording of adverse events
This study is completed, as verified in May 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ALK-Abelló A/S